OneMedNet Executes on Growth Strategy: Secures Over $3 Million in New Bookings, Surpassing Full-Year 2025
OneMedNet Corp. (Nasdaq: ONMD) said it secured more than $3 million in new bookings for 2026 as of June 10, exceeding full-year 2025 bookings, and expects substantially all to convert to revenue by end of Q3 2026, according to the company. Growth is tied to demand for regulatory-grade multi-modal real-world data via its iRWD platform.
How this was made
The 30-second read
Why it matters
The company reports a step-change in commercial momentum (bookings) and provides a concrete expected revenue conversion window (by end of Q3 2026), which can re-rate near-term growth expectations.
Market read
A fresh bookings milestone that exceeds full-year 2025 and is expected to convert to revenue by Q3 2026 is a direct catalyst for ONMD’s growth outlook.
What to watch
The release doesn’t quantify total contract value remaining in the pipeline, customer names, or gross margin impact—key for assessing whether bookings-to-revenue converts into earnings power.
Background
OneMedNet provides regulatory decision-grade, AI-driven real-world data (RWD) via its iRWD™ platform, including multi-modal, imaging-centric datasets.
Ticker impact
OneMedNet says it secured over $3M in 2026 bookings to date, surpassing full-year 2025, with revenue conversion expected by Q3 2026.
Likely positive bias for the stock as traders price in faster revenue recognition into Q3 2026.
The release provides specific, time-bound commercial metrics (bookings >$3M YTD; conversion by end of Q3 2026) and ties them to platform demand, which can move expectations even without earnings numbers.
Market effects
Supports the narrative that regulatory-grade real-world data and multi-modal datasets are seeing accelerating enterprise demand.
No specific regional impact beyond US-listed healthcare/AI data services.
Primarily US-focused disclosure, but the regulatory-submission use case is globally relevant for life sciences.
Counterpoint
Bookings growth may not translate into durable profitability; traders may discount if margins, customer concentration, or renewal rates aren’t addressed.
Key entities
- companyOneMedNet Corporation
Nasdaq-listed provider of regulatory decision-grade, AI-driven real-world data; reports >$3M 2026 bookings YTD and expected Q3 2026 revenue conversion.
- product_platformiRWD™ Platform
OneMedNet’s platform for regulatory-grade multi-modal real-world data used for regulatory submissions and AI model development.
- technology_partnerPalantir Foundry
Platform technology powering iRWD™ per the release.
